Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : neog - Neogen's E.Coli Test adopted by Japan -- Ignore unavailable to you. Want to Upgrade?

To: Kurt C. Bender who wrote (109)	12/10/1997 10:42:00 AM
From: R Sandvig	Respond to of 441

Please allow me to hazard a guess. From my military days, I would say it means End Of Message. You will note it always appears at the end....harkens back to the days when communications were not as reliable as they are today. ;-)

To: Kurt C. Bender who wrote (109)	12/10/1997 11:18:00 AM
From: Kramer	Respond to of 441

Neogen Signs Letter of Intent LANSING, Mich., Dec. 10 /PRNewswire/ -- Neogen Corporation (Nasdaq: NEOG - news) announced today that it has entered into a Letter of Intent to acquire substantially all of the assets of Vetoquinol U.S.A., Inc., a wholly owned subsidiary of the French animal health company, Vetoquinol S.A. The Letter of Intent is subject to due diligence which is expected to be completed within thirty days. Located in Tampa, Florida, Vetoquinol U.S.A. is a USDA licensed biologics production firm. The principal products of the company are EqStim(R) and ImmunoRegulin(R). The primary market for EqStim consists of equine veterinarians who use it to stimulate a horse's immune system to fight off infections. The biologic is most commonly used for the treatment of equine respiratory disease complex in conjunction with other therapies. Neogen plans to continue to operate the Tampa production facility. Sales and administrative functions will be relocated to the company's Lexington, Kentucky facility which currently manufactures and markets pharmaceuticals, vaccines and diagnostic, products for the worldwide professional equine market. Vetoquinol S.A. acquired the Florida based operations from ImmunoMed Corporation in 1995 as a part of its strategy to enter the U.S. animal health market. However, the company has since decided to concentrate its growth strategies in Europe. ''In addition to the immunostimulants, the transaction would also include distribution rights to three wound care products that further increase our product offering to our existing professional equine customer base,'' said James Herbert, Neogen president. ''Our Lexington division recorded revenues in the first quarter 86% higher than the prior year, and has shown a compound annual growth of 39% over the past four years.'' Annual revenues for the acquired portion of the Vetoquinol business are approximately $1.3 million. Neogen expects the business to contribute solid profits immediately to its Lexington division. Except for historical information contained herein, the statements made in this press release constitute forward looking statements that involve certain risks and uncertainties. Certain factors may cause actual results to differ materially from those contained in forward looking statements, including those risks detailed from time to time in the company's report on file at the Securities and Exchange Commission. Neogen Corporation is a Lansing, Michigan based company that develops and markets solutions for safety and improved quality in food, agriculture and pharmacologics. The company's Lexington division markets a line of quality equine care products and produces diagnostic tests used in the horse racing industry to protect animal health and the integrity of the sport. ============== eom - stands for end of message. It is used so that you can tell that the entire message is contained on the subject line and don't have to waist time clicking on the message only to find that there is no more to read. Best Regards, Kevin Kramer